JP2004503505A - 医薬用抗炎症エアゾール製剤 - Google Patents

医薬用抗炎症エアゾール製剤 Download PDF

Info

Publication number
JP2004503505A
JP2004503505A JP2002510103A JP2002510103A JP2004503505A JP 2004503505 A JP2004503505 A JP 2004503505A JP 2002510103 A JP2002510103 A JP 2002510103A JP 2002510103 A JP2002510103 A JP 2002510103A JP 2004503505 A JP2004503505 A JP 2004503505A
Authority
JP
Japan
Prior art keywords
amino
formulation according
formulation
pharmaceutical aerosol
methylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002510103A
Other languages
English (en)
Japanese (ja)
Inventor
アーマー，ダンカン，ロバート
ブラウン，デビッド
コングリーブ，マイルズ　スチュアート
ゴア，ポール，マーチン
グリーン，デアレン，ビクター，スティーブン
ホルマン，スチュアート
ジャック，トルクィル，イアン，マクリーン
メイソン，アンドリュー，マクマートリー
モリス，ケアレン
ラムズデン，ナイゲル，グラハム
トーマス，マリアン
ワード，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2004503505A publication Critical patent/JP2004503505A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002510103A 2000-06-16 2001-06-15 医薬用抗炎症エアゾール製剤 Pending JP2004503505A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0014881.7A GB0014881D0 (en) 2000-06-16 2000-06-16 Pharmaceutical aerosol formulation
PCT/GB2001/002613 WO2001095925A1 (en) 2000-06-16 2001-06-15 Pharmaceutical anti-inflammatory aerosol formulation

Publications (1)

Publication Number Publication Date
JP2004503505A true JP2004503505A (ja) 2004-02-05

Family

ID=9893882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002510103A Pending JP2004503505A (ja) 2000-06-16 2001-06-15 医薬用抗炎症エアゾール製剤

Country Status (5)

Country Link
EP (1) EP1289539A1 (de)
JP (1) JP2004503505A (de)
AU (1) AU2001264113A1 (de)
GB (1) GB0014881D0 (de)
WO (1) WO2001095925A1 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds

Also Published As

Publication number Publication date
AU2001264113A1 (en) 2001-12-24
WO2001095925A1 (en) 2001-12-20
GB0014881D0 (en) 2000-08-09
EP1289539A1 (de) 2003-03-12

Similar Documents

Publication Publication Date Title
CN100398094C (zh) 福莫特罗超细制剂
EP1248597B1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
US7220403B2 (en) Pharmaceutical formulation of fluticasone propionate
JP4380802B2 (ja) 医薬用エアロゾル組成物
US20030206870A1 (en) Pharaceutical aerosol composition
US20130143849A1 (en) Use of ciclesonide for the treatment of respiratory diseases
CN101502500A (zh) 含有β2-激动剂的溶液的加压计量吸入器
US20040136918A1 (en) Pharmaceutical formulations
WO2001028535A2 (en) Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
JP2004503505A (ja) 医薬用抗炎症エアゾール製剤
JP2004503488A (ja) 医薬用抗炎症エアゾール製剤
GB2392164A (en) Pharmaceutical formulation of fluticasone propionate
EP1231894B1 (de) Pharmazeutische formulierungen enthaltend salmeterol
CA2446562C (en) Pharmaceutical formulation of fluticasone propionate
US20050048001A1 (en) Pharmaceutical formulations of salmeterol
WO2002072067A2 (en) Pharmaceutical aerosol formulation
GB2385596A (en) Pharmaceutical formulation of fluticasone propionate
CA2486805A1 (en) A metered dose inhaler containing a pharmaceutical formulation of fluticasone propionate
AU4382701A (en) Pharmaceutical aerosol composition